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ABSTRACT
JACQUELINE MCGRATH: NEUROPROTECTION WITH NOVEL ANTI-OXIDANT
AND CANNABINOID-BASED SMALL MOLECULES
(Under the direction of Dr. Nicole Ashpole)
Neurodegenerative diseases are caused by various underlying mechanisms within
the nervous system. Excitotoxicity is a hallmark of many neurodegenerative diseases, and
is produced by over excitation of glutamate receptors on neurons, ultimately leading to
cell death. Protein aggregates and oxidative stress have also induced neuronal cell death
that lead to many neurodegenerative diseases as well. Many compounds isolated from
plants have shown protective ability against these underlying toxicity mechanisms. In this
study, we tested several cannabinoid and anthyocanin-based small molecules protective
abilities against excitotoxicity. We found several compounds that protected against
glutamate-induced excitotoxicity in a concentration-dependent manner. We also tested
whether cannabinoid-based small molecules could protect against protein aggregate and
oxidative stress toxicity, although our assays require further validation. We are now
working on creating concentration-dependent response curves for the anti-oxidant based
small molecules against excitotoxicity. Future application of these findings would include
administering the neuroprotective compounds to animals to prevent neurodegeneration
and its accompanying behavioral deficits.
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I. Background
As medicine advances, researchers are constantly searching for new drug
therapies to combat disease. Many drug discoveries made utilize therapeutic extracts and
compounds that already exist in nature because non-natural products often result in
increased adverse side effects in treatment of disease (Lahlou 2013). Natural products are
produced from plants, animals, or microorganisms and can be harvested and isolated for
human use. Natural products include secondary metabolites produced by these types of
organisms for defense within the organism or defense against a predator (Mushtaq 2018).
For example, resveratrol is a strong anti-oxidant found in many fruits, such as red grapes,
blueberries, and cranberries that is effective in preventing or fighting infections in the
plant. It has also been shown to alleviate the pathologies of several diseases (Rehman et
al 2018). Type 2 diabetes mellitus is a disorder that causes glucose intolerance and
hyperglycemia. Resveratrol and vitamin E made mice with type 2 diabetes mellitus more
glucose tolerant, and lowered their hyperglycemia (Rehman et al 2018). Alzheimer’s
disease is a neurodegenerative disease that is characterized by -amyloid peptide
aggregates surrounding neurons. When neurons were treated with both amyloid betapeptide1-42 and resveratrol, apoptosis and oxidative stress were significantly reduced in
the neuronal cell lines (Wang et al 2018). Like resveratrol, there have been many other
studies that emphasize the therapeutic effects of natural products and their constituents on
a diverse range of human disease, including neurodegenerative diseases.
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As the human life expectancy has slowly increased throughout all the years of
medical advancements, there has also been a growing concern about the aging brain.
With a larger population of older adults worldwide, there is a corresponding increase in
the number of cases of neurodegenerative diseases, such as Alzheimer’s disease and
Parkinson’s disease. It is estimated that about 5 million Americans are currently
diagnosed with Alzheimer’s disease and 500,000 are currently diagnosed with
Parkinson’s disease (NIEHS 2019). With the number of people affected by age-related
neurodegenerative diseases, there has been research with natural product therapeutics that
hope to prevent or delay the onset of neurodegenerative diseases and age-related
cognitive impairment.
Many of the neurodegenerative diseases researchers are interested preventing
neuronal death, also known as neurotoxicity, associated with neurodegenerative diseases.
Neurotoxicity is when a certain exposure to natural or manmade toxic substances changes
normal neuron activity, disrupts homeostasis, and leads to cell death (NINDS 2018).
Excitotoxicity, protein aggregates, and oxidative stress are some of the known underlying
mechanisms by which neurotoxicity is induced in neurons. Excitotoxicity is a
neurodegenerative pathway in which the over-excitation of glutamate receptors causes
too much calcium influx in neurons and ultimately leads to cellular necrosis and
apoptosis (Choi 1985, Mattson 2019). Amyloid-beta peptide plaques, or other protein
aggregates, are a characteristic found in Alzheimer’s disease. The amyloid-beta1-42
peptide acts as an agonist ligand to receptors that initiate apoptosis in neurons, decreasing
neuronal cell viability in people diagnosed with Alzheimer’s disease (Sotthibundhu
2008). In neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease,
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and Amyotrophic Lateral Sclerosis, reactive oxygen species produced as by-products of
cellular metabolism mediate neuronal apoptosis (Khan et al 2016, Ricart, Fiszman 2001).
Excitotoxicity, amyloid-beta peptide aggregates, and reactive oxygen species all induce
neurotoxicity through different pathways, yet they converge and mediate neuronal death
in many well-known neurodegenerative diseases.
Many natural products are now being tested for their protective effects against
these neurotoxic substances in order to find therapeutic discoveries for neurodegenerative
diseases. Anthocyanins are compounds that provide the red, purple, and blue pigments in
many fruits and vegetables. These compounds are polyphenols that belong to the
flavonoid family, and are known for being strong anti-oxidants that protect against a
diverse range of toxins within the body (Badshah et al 2014). Polyphenols are chemical
structures widely produced by plants that protect against ultraviolet radiation and other
toxins (Pandey 2009). Because of their protective properties, many anthocyanin-rich
extracts are being tested for their protection against reactive oxygen species/oxidative
stress in neurodegenerative diseases. Anthocyanin extracts are protective against
neurodegeneration caused by oxidative stress and inflammation in vitro and in vivo (Khan
et al 2016, Kim et al 2017, Vepsäläinen 2013). In a study performed by Badshah et. al.,
anthocyanin extracts also decreased neuronal cell death following exposure to amyloidbeta, suggesting they can protect against multiple pathways that cause neurodegeneration
(Badshah et al 2014). Because of anthocyanin extracts’ protective properties observed in
common neurodegenerative pathways, the entire class of compounds and their derivatives
are potential candidates for neuroprotection. Thus, in this study we explore the potential
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of several anthocyanin derivatives for their ability to protect neurons from the various
neurodegenerative mechanisms in vitro.
Another interesting set of natural products are those found in Cannabis sativa.
Cannabis has been used for potential therapeutic purposes in humans for centuries,
although we still understand very little about the protective compounds produced by
cannabis. Its first origins in Central Asia, it resembles a weed-like plant and grows in wet
environments. Cannabis sativa is thought to have been domesticated by humans early in
history, with pre-civilization humans settling near bodies of water where the plant
flourished. Because of its long-term domestication, it has been used by humans in the
forms of textiles, antibacterial agents, and medicines (Andre et al 2016, Pollio 2016).
While cannabis produces many classes of compounds, the two most prevalent are
terpenes and cannabinoids. Cannabinoids found in cannabis are termed
phytocannabinoids, translating to plant-derived cannabinoids. There are also synthetic
and endogenously-produced cannabinoids (Campos 2016). The parent cannabinoids of
interest in this study are two phytocannabinoids, cannabidiol (CBD) and ∆9tetrahydrocannabinol (THC). CBD can be therapeutic and neuroprotective against
neurodegenerative diseases because of its anti-inflammatory and anti-oxidant properties
(Ruet et. al. 2013). Although THC is more psychoactive than CBD (Ruet et. al. 2013), a
recent study has shown that a chronic low dose of THC can restore learning and memory
in aged mice (Bilkei 2017). Because of previous findings on the protective effects of both
CBD and THC, it makes their derivatives active candidates for this study.
Anthocyanins, CBD, and THC have all shown protective abilities in previous
studies. Because of their known protective properties, it is worth examining potential
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protective properties of the derivatives of these compounds. In this study, we hypothesize
that anthocyanin and cannabinoid-based small molecules will protect neurons from
excitotoxicity and other mechanisms of neuronal death. To explore this, we will culture
neurons from rodents and treat them with novel anthocyanin and cannabinoid derivatives
prior to treating them with excitotoxic insult. Cell death will then be measured.
Ultimately, this study will highlight whether these compounds have protective potentials
that should move into animal models of neurodegeneration.
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II. Methods
Neuron Culture Preparation
Before neurons were cultured, the 96-well plates were prepared by coating them
with 60 microliters of 0.01% Poly-L-Lysine, and placing them in the incubator for 24
hours. After 24 hours, the 96-well plates were washed twice with distilled water, and
dried before use. The poly-lysine is added to give the neurons a surface to attach to on the
plastic dishes.
Two petri dishes and five 15 mL conical tubes were placed in ice and cold HBSS
was added to prepare for tissue isolation. The neurons that were to be cultured and used
in the experiment were the cortical neurons of embryonic rats (day 16-18). After
removing the embryo, the animals were decapitated and the brain was removed and
placed in one of the petri dishes of HBSS for dissection. In order to harvest the cortical
neurons, an incision first had to be made down the brain’s midline and horizontally
across the occipital bone of the skull. After removing the skull, the hemispheres were
separated and the meninges of the brain were removed to access the cortex. The left and
right hemisphere were separated, and the cortices of both were diced into fine pieces and
placed in the 15 mL tubes of HBSS. After pieces of the cortex were added to the tubes,
papain was also added. Papain enzymatically digested the tissue for 20-25 minutes at
37°C before being washed out twice with media. For mechanical digestion, the cells were
subjected to successional pipetting. The cells were suspended in growth media and the
cell count was recorded by placing the cells on a hemocytometer in order to ensure that
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there would be the proper number of cells for plating. There were approximately 250,000
cells per well in this experiment. One-hundred microliter of growth media was plated on
96-well plates and stored in the incubator for twenty-four hours. The growth media
consisted of neurobasal media, L-glutamine, fetal bovine serum (FBS), and penicillinstreptomycin. After incubating for 24 hours, the 100 microliter neurobasal media with
serum was removed and replaced with 100 microliter fresh neurobasal media that did not
include serum. The fresh neurobasal media without serum consisted of neurobasal media,
L-glutamine, B27, and penstrep. After adding the fresh neurobasal media, the plates
remained in the incubator until time of treatment (Ashpole, 2011).

Figure 1: Healthy neuron culture grown under the neuron preparation stated above.
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Excitotoxicity Treatment:
Because the compounds used in the experiment were testing for neuroprotection,
the cultured neurons were exposed to glutamate and complete neurobasal media in order
to induce excitotoxicity and reduce cell viability in the neuron cultures. Complete
neurobasal media was warmed in a water bath at 37°C for 10 minutes. A 50 mL conical
was used to collect the complete neurobasal media and glutamate. For every milliliter of
complete neurobasal media used, one microliter of 200 millimolar glutamate was added
to the conical to make a 200 micromolar glutamate media stock. This 50 mL conical was
then labeled as “E-media.” A pipette was used to thoroughly mix the newly made Emedia. Using an automatic pipette, 1 mL of the E-media was added to each individual 1.5
mL microtube. The potential protective compounds of interest were then added to these
1.5mL tubes prior to application on the cells (see anthocyanin and cannabinoid sections
below).

Amyloid-Beta Treatment
Amyloid-Beta was used as another method to induce neurotoxicity on the cultured
neurons in order to test the CBD derivatives’ neuroprotective abilities. Complete
neurobasal media was removed from the refrigerator and placed in a water bath at 37°C
for 10 minutes. -Amyloid Peptide1-42 was removed from the freezer at -20°C and thawed
under the fume hood. Once thawed, 7.5 microliters of 5 millimolar A1-42 were pipetted
into 15 mL of complete neurobasal media in a 15 mL conical giving a final concentration
of 2.5 micromolar. Twenty-six microtubes were then filled with 400 microliters each of
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the AB/media solution so we could add the potential neuroprotective compounds prior to
application on the neurons.

Hydrogen Peroxide Treatment
Hydrogen peroxide was used as a method to induce neurotoxicity through
oxidative stress on the cultured neurons in order to test the CBD derivatives’
neuroprotective abilities. Hydrogen peroxide is a reactive oxygen species that can often
be produced as a by-product of oxygen metabolism in cells. When there is an imbalance
and large production of hydrogen peroxide, it is called oxidative stress and it induces cell
death (Ricart, Fiszman 2001). Complete neurobasal media was removed from the
refrigerator and placed in a water bath at 37°C for 10 minutes, and 1.5 microliters of 9.8
molar peroxide was diluted into 1.5 mL of distilled water to make a 9.8 millimolar
peroxide stock. A 50 mL conical was filled with 26 mL of neurobasal complete media,
and 408 microliters of the 9.8 millimolar peroxide was pipetted into the neurobasal
complete media to give a final stimulation media of 150 micromolar. Peroxide media (1
mL) was pipetted into each of the 26 microtubes and the compounds of interest were then
added (see below).

Anthocyanin Derivatives Treatment:
Twenty-three compounds based on anthocyanins found in blueberries were tested
for neuroprotection. The compounds were suspended in a solution of dimethyl sulfoxide
(DMSO) at 10 millimolar concentrations. The compounds and extracts were received
from Dr. Colby in conjunction with the Department of BioMolecular Sciences. Due to
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intellectual property rights, the compounds are labeled as numbers throughout this report,
rather than their chemical name.
Using a pipette, 1 mL of the E-media was pipetted into each of the 23 microtubes.
Each microtube received 2 microliters of a specific compound so that the final
concentration of the test compound was 5 micromolar. After the compound was added,
the microtube lid was labeled with that compound’s corresponding number. After all of
the 23 tubes contained E-media and one compound, three 96-well plates were removed
from the incubator. Each column on each plate was designated to a specific compound,
and all of the wells of that column received 100 microliters of the compound/E-media
solution contained in the specific microtube. Control wells received 100 microliters of
complete neurobasal media, and two columns contained 100 microliters of E-media in
their wells. The plates were placed back in the incubator for 1-2 hours. The same process
as stated previously was repeated but with concentrations of 4 microliters of compound
and 8 microliters of compound in E-media solution so that the final concentration of the
test compound was 20 micromolar and 40 micromolar, respectively. After the incubation,
the plates were then subjected to several washes. One-hundred fifty microliters were
removed from all of the wells of the plate, and discarded. Then, 100 microliters of fresh
neurobasal complete media were added to all of the wells of the plates, then immediately
the 100 microliters of the fresh complete neurobasal media were then removed and
discarded. Finally, 50 microliters of fresh complete neurobasal media were added to all of
the wells on all of the plates, and placed in the incubator for 24 hours.
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Cannabinoid Derivative Treatment:
Twenty-six cannabinoid compounds were used in this experiment. The
compounds were suspended in a solution of dimethyl sulfoxide (DMSO) at 10 millimolar
concentrations. The compounds and extracts were received from Dr. Majumdar and Dr.
ElSohly in conjunction with the National Center for Natural Product Research. Due to
intellectual property rights, the compounds are labeled as numbers throughout this report,
rather than their chemical name.
Fifteen of the compounds were first tested on neuron cultures. Using a pipette, 1
mL of the E-media was pipetted into each of the 15 microtubes. Two microliters of a
specific CBD compound were then added to one of the 15 microtubes so that the final
concentration of compound was 10 micromolar. Then the lid of that microtube was
labeled with the corresponding compound’s labeling number. Once all of the microtubes
contained 2 microliters of a certain CBD compound, 96-well plates were removed from
the incubator. Each microtube’s contents were pipetted in a specific column of wells,
with each well receiving 100 microliters. Two control columns received 100 microliters
of E-media in each of their wells, and one control column received 100 microliters of
fresh neurobasal complete media in each of its wells. Once all plates were treated with
the 2 microliters of compound solution, they were placed back in the incubator for 1-2
hours. Using the same steps above and the same compounds, this process was repeated
three different times with three different sets of plates with 4 microliters of compounds, 6
microliters of compounds, and 8 microliters of drug in the microtubes for a final
concentration of 20 micromolar, 30 micromolar, and 40 micromolar, respectively. All of
these plates were also placed in the incubator for 1-2 hours. After incubation, all plates
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were removed subjected to washings. One-hundred fifty microliters from all of the wells
were removed and discarded. One-hundred microliters of fresh complete neurobasal
media were added, and then the 100 microliters of fresh complete neurobasal media were
removed and discarded. Finally, 50 microliters of fresh complete neurobasal media was
added and all plates were placed in the incubator for 24 hours.
All 26 compounds were then tested for their neuroprotection against glutamate on
neuron cultures. Using a pipette, 1 mL of the E-media was pipetted into each of the 26
microtubes. Three point five microliters of a specific CBD compound were then added to
one of the 26 microtubes, so that the final concentration was 17.5 micromolar. The lid of
that microtube was then labeled with the corresponding compound’s number. Once all of
the microtubes contained 3.5 microliters of a certain CBD compound, 96-well plates were
removed from the incubator. Each microtube’s contents were pipetted in a specific
column of wells, with each well receiving 100 microliters. One column received 100
microliters of E-media in each of its wells, and one column received 100 microliters of
fresh neurobasal complete media in each of its wells. Once all plates were treated with
the 17.5 micromolar compound solution, they were placed back in the incubator for 24
hours. The following procedures described above were repeated with derivative
concentrations of 5 micromolar, 10 micromolar, and 40 micromolar.
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Figure 2: The workflow of concentration-response compound treatment on glutamate
insulted neurons.

All 26 compounds were then tested for their neuroprotection against amyloid-Beta
(AB) on the neuron cultures. Using a pipette, 1 mL of the AB-media was pipetted into
each of the 26 microtubes. Each microtube then received 1.6 microliters of a specific
compound so the final concentration of compound was 20 micromolar, and that
microtube was labeled with the compound’s corresponding number. Three 96-well plates
of cultured neurons were then removed from the incubator to be treated. Fifty microliters
of media were removed from all of the wells on the plate before the plates were treated
with any of the compound and AB solution. Once the 50 microliters of media were
removed, 50 microliters of a specific compound and AB media were pipetted into each
well of a specific column. This was repeated until each compound had its own column of
treated cells. One column received 100 microliters of AB media in each of its wells, and
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one column received 100 microliters of fresh neurobasal complete media in each of its
wells. The plates were then placed in the incubator for 24 hours.
All 26 compounds were then tested for their neuroprotection against peroxide
(H2O2) on neuron cultures. Using a pipette, 1 mL of the H2O2-media was pipetted into
each of the 26 microtubes. Three point five microliters of a specific compound was
pipetted into each microtube so the final concentration was 17.5 micromolar, and then the
microtube was labeled with the compound’s corresponding number. Once all of the
microtubes contained 3.5 microliters of a certain CBD compound, 96-well plates were
removed from the incubator. Each microtube’s contents were pipetted in a specific
column of wells, with each well receiving 100 microliters. One column received 100
microliters of peroxide and media in each of its wells, and one column received 100
microliters of fresh neurobasal complete media in each of its wells. Once all plates were
treated with the 3.5 microliters of compound solution, they were placed back in the
incubator for 24 hours.
Eight of the CBD compounds underwent an individual concentration curve using
the 200 micromolar E-media stock for excitotoxicity insult. Each of the compounds had
their own 96-well plate. For each of the 8 compounds, a 10-fold dilution in microtubes
was done. The first microtube contained 16 microliters of one of the compounds into 1.5
mL of the E-media, so the final concentration was 100 micromolar. Seven-hundred fifty
microliters of the first microtube was then pipetted into the second microtube containing
750 microliters of E-media, so its final concentration was 50 micromolar. This was
repeated 8 times, until a final concentration of 0.195 was reached in the last microtube.
Each concentration had a specific column on the 96-well plate, with each well receiving
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90 microliters of that specific concentration. Every plate contained one column of fresh
media and one column untouched. After all of the 8 compounds had their concentrations
plated, they were placed in the incubator for 24 hours.

MTS Assay
After the neurons were treated with the compounds and the neurotoxicity insults,
the plates were placed in the incubator for 24 hours. In order to determine the number of
viable cells left in the plates, the MTS assay was performed on the plates. The solution
used in the experiments to perform the MTS assay was CellTiter 96 AQueous One
Solution Reagent. This reagent includes tetrazolium salt and an electron coupling reagent.
MTS is used to detect viability because viable cells with active metabolisms can change
MTS into formazan. When MTS is changed to formazan, a color change from a pale
yellow to dark purple is seen in the wells. The tetrazolium detects viable cells, and is
reduced by the electron coupling aspect of the reagent to form the colored formazan that
is seen (Riss et al 2013). The MTS AQueous One Solution Reagent was kept in the freezer
at -20°C, and thawed out for 10 minutes before use. Ninety-six well plates with treated
neurons were removed from the incubator, and 5 microliters of MTS was added to each
of the wells for the anthocyanin compounds, and 2.5 microliters of MTS was added each
of wells for the CBD compounds. Once the MTS AQueous One Solution Reagent was
added to each of the wells, the plates were placed back in the incubator for 1-2 hours.
After the plates were removed, a color change from yellow to dark purple was observed
for certain wells. The plate was then put in the plate reader, and the wells were at an
absorbance at 490 nm.
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Figure 3: Workflow of MTS Assay.

Live/Dead Viability/Cytotoxicity Assay
After MTS was ran, Live/Dead Viability/Cytotoxicity was then run on the plates
of different concentrations for the 8 specific cannabinoid compounds. The Live/Dead
assay uses two fluorescent stains simultaneously to mark live and dead cells. Intracellular
esterase activity and an intact plasma membrane are strong indicators for live cells. The
Live/Dead Assay uses calcein-AM to mark intracellular esterase activity, and ethidium
homodimer-1 to mark cells without intact plasma membranes. When examined under
fluorescent microscopy, the calcein-AM fluoresces green and the ethidium homodimer-1
fluoresces red. Per manufacturer recommendation (L3224), the calcein and ethidium
homodimer-1 were stored in the freezer at -20°C and protected from light. To make the
solution, 160 microliters of 2 millimolar ethidium homodimer-1 was added into 80
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microliters of PBS. Then, 40 microliters of calcein was added to 80 milliliters of the
ethidium homodimer-1 and PBS solution. The 80 milliliter was then vortexed, yielding a
2 micromolar calcein AM and 4 micromolar ethidium homodimer-1 working solution.
100 microliters of working solution is then added directly to each well. The solution
remained in each well for 30-45 minutes at room temperature protected from light, then
were taken to be visualized on the fluorescent microscope.

Data Analysis
All data from the plate reader was exported and saved in Excel. The absorbance
data from each compound’s column was averaged. These averages of the absorbances
were then exported into SigmaPlot, where graphs of average cell viability were
constructed and the variance was analyzed. All data was normalized to the control in both
Excel and SigmaPlot. SigmaPlot was used to create the graphs of the data, and to run
analysis of variances in the data. In the bar graphs, data was shown as averages of the
data and error bars represent plus/minus standard error measurement ( SEM). A oneway ANOVA using multiple groups was used to examine statistical analyses and
variance between the cannabinoid derivatives and anthocyanin derivatives. After the
ANOVA analysis was ran, a Dunnett’s post hoc test assessed significant variance against
the control at p<.05 for each derivative in the cannabinoid and anthocyanin derivative
excitotoxicity insult bar graphs. For the CBD and THC derivative concentration viability
scatter plots, scatter points represented means and the bars represented plus/minus one
standard error measurement. The scatter plot data is plotted in linear form.
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III. Results
We established neuron cultures from rat cortices and grew cells in vitro for 8-10
days prior to treatment. After the neurons were developed in culture, the neurons were
treated with an excitotoxic level of glutamate, in combination with the cannabinoid and
anti-oxidant small molecules. These prodrugs and derivatives were provided by Dr.
David Colby, Dr. Mahmoud ElSohly, Dr. Soumyajit Majumdar, and the National Center
for Natural Product Research.
All cells were assessed for viability using MTS assay 24 hours after treatment.
Because each column of a 96-well plate was treated with the insult and derivative, all
data on the graphs represent the viability average of 8 wells of treated neurons. All
averages were normalized to control. DMSO labels in all bar graphs reflect neuron
cultures that were treated with just the toxic treatment (glutamate, amyloid-beta, or
peroxide), and no protective compounds.
To first assess the amount of glutamate needed to induce excitotoxicity, cultured
neurons were treated with increasing concentrations of glutamate (Figures 4-5). As the
concentrations of glutamate on neurons increased, there was a significant decrease in
cell-viability at the 100 and 200 micromolar concentrations of glutamate. This set the
baseline for a 200 micromolar glutamate concentration to be used in the experiment to
induce neurotoxicity and reduce cell viability.
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Figure 4: Increasing concentrations of glutamate reduce neuronal viability. The 100 and
200 micromolar concentrations significantly decreased cell viability, as indicated by the
asterisks. This significance was verified using a One-Way ANOVA with a Dunnett’s
post-hoc test.
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Figure 5: Visualization of MTS assay after glutamate concentration curve treatment. A
pale color well is indicative of a low cell density, meaning cells have died. A dark purple
color well is indicative of a higher cell density, because more cells are alive and actively
metabolizing to convert the tetrazolium salt into formazan. The left side of the plate
received the excitotoxic insult for a 24-hour insult period, while the right side of the plate
received a limited insult time for 1 hour. The 24-hour insult killed more cells than
anticipated, and it would be difficult to find a drug that would protect against the 24 hour
excitotoxic insult. This established that our excitotoxic insult needed to be 1 hour.
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The protective ability of the cannabinoid and anthocyanin small molecules against the
200 micromolar insult was then assessed using a 10 micromolar concentration of each of
the compounds (Figures 6-7). For both sets of these compounds, an ANOVA statistical
analysis with a Dunnett’s post-hoc test was run to evaluate significant differences from
control. There were many protective hits on several compounds in both the cannabinoid
and anthocyanin-based experiment. CBD, CBD derivative 1, CBD derivative 3, CBD
derivative 4, THC derivative 2, and THC derivative 3 were all significantly protective
against the excitotoxic insult. Anthocyanin-based compounds 1, 2, 3, 6, 10, 11, and 12
were all significantly protective against the excitotoxic insult. After testing all
cannabinoid derivatives against the glutamate insult, CBD, CBD derivative 1, CBD
derivative 2, CBD derivative 3, CBD derivative 4, CBD derivative 5, CBD derivative 6,
THC derivative 2, THC derivative 3, THC derivative 4, and THC derivative 5 were all of
interest for concentration-response curves (Figures 8-9). Increasing concentrations of 5,
10, and 40 micromolar of the derivatives were applied to the glutamate induced cultured
neurons, and viability was assessed 24 hours later. In both Figure 8 and Figure 9, a
concentration-dependent response can be seen for both the CBD derivatives and THC
derivatives. The compounds’ protective ability against glutamate-induced toxicity
increases as the compound concentration increases. Between the 10 micromolar and 40
micromolar concentrations, protective abilities of the derivatives begin to plateau, seen in
Figure 8 and Figure 9.
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Figure 6: Several of the CBD and THC derivatives when treated at a 10 micromolar
concentration were protective against the 200 micromolar glutamate insult, indicated by
asterisks. DMSO reflects wells that received only the excitotoxic insult. The control bar
is reflective of wells that were unstimulated, and received no treatments. The compounds
were compared to the DMSO control, and significance was verified using a One-Way
ANOVA with a Dunnett’s post-hoc test.
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Anthocyanin-based compound #

Figure 7: Several of the anthocyanin derivatives when treated at a 10 micromolar
concentration were protective against the 200 micromolar glutamate insult, indicated by
asterisks. DMSO reflects wells that received only the excitotoxic insult. The control bar
is reflective of wells that were unstimulated, and received no treatments The compounds
were compared to the DMSO control, and significance was verified using a One-Way
ANOVA with a Dunnett’s post-hoc test.
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Figure 8: The CBD derivatives showed a concentration-dependent response in
protection. Their protection increases up to the 10 micromolar concentration, then the
compounds were maximally protective.
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Figure 9: The CBD derivatives show a concentration-dependent response in protection.
Their protection increases up the 10 micromolar compound concentration, then the
compounds are maximally protective.
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Because of the protection seen in the CBD and THC derivative treated
excitotoxicity neuron cultures, their protection was tested in amyloid-beta and peroxide
treated neuron cultures. In the amyloid-beta treated cell cultures, amyloid-beta
statistically significantly reduced cell viability, but none of the compounds protected
against its toxicity (Figure 10). In the peroxide treated cell cultures, the peroxide did not
effectively induce toxicity or decrease neuronal viability, so there was not a window to
show neuroprotection with the compounds of interest (Figure 11). A full concentrationresponse curve for H2O2 needs to be performed to identify a level of H2O2 that kills our
cultured neurons.
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*

Figure 10: The CBD and THC derivatives were not protective against a 2.5 micromolar
concentration of amyloid-beta. The control bar reflects wells of cells that were
unstimulated. The DMSO bar reflects wells of cells that just received the amyloid-beta
insult.
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Figure 11: The peroxide did not reduce cell viability significantly, so the protective
abilities of the CBD and THC derivatives could not be assessed. The control bar reflects
wells of cells that were unstimulated. The DMSO bar reflects wells of cells that just
received the peroxide insult.
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IV. Discussion
We observed that several of the cannabinoid and anthocyanin small molecules
showed neuroprotective capabilities in vitro. At the 10 micromolar concentration, both
sets of cannabinoid and anthocyanin-based compounds had specific hits that were
protective against glutamate-induced excitotoxicity. Although the anthocyanin
derivatives were only tested at one concentration against one stressor (excitotoxicity),
these data show the protective capabilities of the anthocyanin-derivatives in vitro. In
previous research, the protective abilities of anthocyanins against amyloid-beta induced
toxicity have been reported. Anthocyanins from black soybeans treated in combination
with amyloid-beta increased cell viability and reduced cell apoptosis (Badshah et. al.
2014). We did not observe any neuroprotection against amyloid-beta with the compounds
of interest. Examining the effects of the anthocyanin derivatives in this study against
amyloid-beta toxicity will be an interesting future study, with potential clinical
applications. Thus, it is important to repeat this study.
After treating neurons with increasing concentrations of CBD and THC
derivatives of interest, there was a concentration-dependent response of protection in our
excitotoxic glutamate assay. Because of their protection against excitoxocity, CBD
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derivatives 1-6 and THC derivatives 2-5 could be used as potential therapeutic agents
against neurodegenerative diseases such as Alzheimer’s disease, epilepsy, and
amyotrophic lateral sclerosis. Some of the previous CBD and THC-based drugs have
been removed from the commercial market because of their adverse side effects (Badal et
al 2017), so it will be important to assess whether these derivatives could cause
neuroprotection in animals without inducing adverse effects.
It would also be interesting to investigate how the cannabinoid derivatives’
antioxidant properties would affect inflammation that accompanies many of these
neurodegenerative diseases. The inflammation and microglial activation causes indirect
decreases in neuronal viability in Alzheimer’s disease (Ramírez et al 2005). In a study by
Ramírez et al., cannabinoid analogs in vitro were also unable to prevent toxicity directly
induced by amyloid-beta in cortical neuron cultures, but some analogs were protective
against the indirect toxicity caused by inflammation and microglia activation (Ramírez
2005). The cannabinoid agonist WIN55,212-2 used in vivo in the 2005 study also
prevented cognitive impairment in amyloid-beta treated rats without adverse side effects
(Ramírez 2005). Although the cannabinoid analogs did not prevent toxicity induced by
amyloid-beta directly, the research with other cannabinoid analogs against amyloid-beta
toxicity provides implications for some of the protective abilities of the cannabinoid
derivatives in our study.
In June of 2018, the first CBD-based medication, Epidiolex, was approved by
the FDA to treat people diagnosed with Lennox-Gastaut syndrome and Dravet syndrome.
Both of these syndromes cause seizures beginning in early childhood (FDA 2018).
Although the medication reduced frequency of seizures, side effects of elevated liver
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enzymes, insomnia, diarrhea, and infections were also noted in the study (FDA 2018).
An interesting clinical application would be to see the effects of the CBD-derivatives that
showed protection against excitotoxicity on these seizures. Perhaps, because of slight
differences between the CBD derivatives and CBD, the derivatives would reduce side
effects. This is a speculation, but an interesting area of further study.
The CBD and THC derivatives in this study also could have potential clinical
applications in delaying the onset of amyotrophic lateral sclerosis (ALS). ALS is a
neurodegenerative diseases of motor neurons which are extremely susceptible to
oxidative stress, inflammation, and excitotoxicity (Ludolph et al 2000, Robberecht 2000).
In a study by Raman et al, the progression of ALS in mice was delayed with the
administration of THC after diseases symptoms had already began in the mice (2004).
Although protective, it is unknown what the effects of THC would be in a human model
of ALS because of THC’s known psychoactive properties (Ruet et. al. 2013). Therefore,
there are potential applications of the THC derivatives protection against ALS induced
degeneration, while minimizing psychoactive side effects. Another study has shown how
cannabinoid agonist AM1241 significantly delays progression of ALS in male mice, but
not in female mice (Kim, 2006). It is interesting that the cannabinoid agonist used did not
protect in female mice with ALS. This leads to another potential application of the
protective cannabinoid derivatives in this study. Replicating this experiment with some of
the CBD derivatives to test their protection in animal models, and to analyze if they are
significantly protective in both sexes to find a universal therapeutic agent.
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Limitations of Experiment and Future Directions
There are several experiments that need to be done to improve and advance our
current findings. First, a concentration-response curve for the anthocyanin-based
compounds is needed. While we attempted this, the assay failed as glutamate did not kill
neurons. We are unsure why glutamate did not kill, thus the assay needs repeating.
Because there is not a concentration-response curve, it is unknown how protection
changes with increasing concentrations of the compounds. Another limitation is the fact
that the hydrogen peroxide did not reduce neuronal viability. This assay requires further
validation before making conclusions about the cannabinoid based derivatives
effectiveness in protecting against oxidative stress. The amyloid beta assay also needs to
be validated using a positive control before making conclusions about the effectiveness of
the test compounds.
Because these studies were only conducted in vitro, it is also unknown whether
these compounds can protect neurons in the full, living system. It is important to now test
whether these drugs can be effective within animal models of neurodegeneration.
Moreover, in vivo tests are critical for determining the possible side effects these
derivatives have on other aspects of the human body and its metabolism.
Many future directions can be taken after this study. A concentration-response
curve of the anthocyanin-derivatives should be constructed. This will enable us to see
how the anthocyanin-derivatives protection against excitotoxicity changes with
increasing applications of the derivatives. Anthocyanin-derivatives will also be tested for
their protection against amyloid-beta toxicity and oxidative stress. Because the peroxide
did not reduce neuronal viability in the oxidative stress test in this study, the oxidative
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stress study will also be repeated for the cannabinoid-derivatives in order to accurately
assess their protection against oxidative stress and reactive oxygen species. Live-dead
assays will also be accompanied by future protective assays, in order to accurately
quantify the protective extent of the derivatives. If future in vitro studies show significant
protective abilities of the anthocyanin and cannabinoid-derivatives, future animal models
of learning and memory will be of interest.

Overall Conclusions
In conclusion, there were many significantly protective hits against neurotoxicity
from multiple CBD, THC, and anthocyanin derivatives. We believe that the derivatives
of interest have potential to protect neurons. There is selectivity in the compounds used in
this research, as some were protective against glutamate excitotoxicity, and others were
not. The mechanisms of action of these compounds are unknown, and require further
research. There is also potential in the protective compounds to use their structural
information to create other derivatives that could potentially be more effective in
neuroprotection. We hope that these compounds’ neuroprotective capabilities can be used
and seen in both animal and human models.
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